Clinical development failure
Bempikibart is still in clinical testing, so efficacy or safety results may not support approval.
- Scope
- Lead program in alopecia areata and other autoimmune diseases
- Materiality
- high
Q32 Bio Inc.
Q32 Bio Inc. is a U.S.-based clinical-stage biotechnology company focused on developing biologic medicines for autoimmune and inflammatory diseases. Its lead program, bempikibart (ADX-914), is an anti-IL-7Rα monoclonal antibody being studied for alopecia areata and other immune-mediated conditions.
32,2 %
55,5 %
4.85
4.85
| % | |
|---|---|
| Lead biologic candidate | 100% Bempikibart (ADX-914), a fully human anti-IL-7Rα monoclonal antibody in clinical development. |
| Clinical-stage pipeline | 0% Early- and mid-stage development programs targeting autoimmune and inflammatory diseases. |
Q32 Bio does not sell commercial products today; its current counterparties are clinical trial participants,...
- Clinical trial participantsprimary
Patients enrolled in SIGNAL-AA and other studies who receive investigational bempikibart.
- Clinical investigators and trial sitesprimary
Hospitals, clinics, and investigators that recruit, dose, and monitor patients in studies.
- Third-party manufacturersprimary
Contract manufacturers that supply biologic drug substance and drug product for development.
- Future prescribers and payorssecondary
Physicians and reimbursement bodies that would determine adoption after approval.
Q32 Bio is headquartered in Waltham, Massachusetts and incorporated in Delaware, with its principal operations centered...
- •Headquartered in Waltham, Massachusetts
- •Incorporated in Delaware, United States
- •Clinical and corporate operations are U.S.-based
- •Future approvals may target selected foreign jurisdictions
Q32 Bio's strategy is centered on advancing bempikibart through clinical development in alopecia areata and evaluating...
01
Complete clinical development of bempikibartshort-term
Clinical data are the main value driver for a single-asset biotech.
02
Expand the therapeutic opportunity beyond one indicationmedium-term
Broader autoimmune use could increase the commercial value of the platform.
03
Maintain manufacturing and development flexibilitymedium-term
Biologics require reliable external supply and process control.
Q32 Bio faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, dependence on external capital,...
Need for external financing
The company does not expect current cash to fund development through approval.
- Scope
- Pipeline advancement and potential commercialization
- Materiality
- high
Manufacturing dependence
Biologic supply relies on third-party vendors and specialized production capability.
- Scope
- Clinical supply and future commercial scale-up
- Materiality
- high
Regulatory and reimbursement uncertainty
Approval, labeling, and payer coverage will determine whether any future product can be commercialized.
- Scope
- U.S. and selected foreign markets
- Materiality
- high
Research and development expense
Affects operating loss and comparability across quarters
Collaboration arrangement revenue
Can create large one-time revenue and earnings swings
Fair value measurements
Can distort underlying operating performance
Stock-based compensation
Raises reported operating expense without cash outflow
ImageneBio, Inc.
IMA · Biological Products, (No Diagnostic Substances)
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Dianthus Therapeutics, Inc. /DE/
DNTH · Pharmaceutical Preparations
Dianthus Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for autoimmune and inflammatory diseases.
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
: 29/04/2026